EQS-Ad-hoc: Redcare Pharmacy N.V. / Key word(s): Regulatory Approval Redcare Pharmacy’s CardLink solution extended by gematik. Sevenum, 15 July, 2025. Through its technology partner, eHealth Experts, Redcare Pharmacy N.V. today received confirmation that its CardLink solution license for the redemption of e-prescriptions in Germany has been extended by the German National Digital Health Agency (gematik) until 31 January 2027 (from previously 31 March 2026). With this extension, Redcare Pharmacy’s access to the German e-prescription market remains secured during the transition to the new Proof of Patient Presence (PoPP) infrastructure.
Contact: rikutis consulting Thomas Schnorrenberg Cel: +49 151 46 53 13 17 E-Mail: presse@shop-apotheke.com End of Inside Information
15-Jul-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Redcare Pharmacy N.V. |
Erik de Rodeweg 11-13 | |
5975 WD Sevenum | |
Netherlands | |
Phone: | 0800 - 200 800 300 |
Fax: | 0800 - 90 70 90 20 |
E-mail: | investors@redcare-pharmacy.com |
Internet: | www.redcare-pharmacy.com |
ISIN: | NL0012044747, DE000A19Y072 |
WKN: | A2AR94, A19Y072 |
Indices: | MDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2169930 |
End of Announcement | EQS News Service |
|
2169930 15-Jul-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.